Start Date
May 31, 2015
Primary Completion Date
August 31, 2016
Study Completion Date
August 31, 2016
RUXOLITINIB / INC 424
Administered orally 5-20 mg twice daily x 16 weeks of therapy prior to attempted peripheral blood stem cells (PBSC) collection, during the collection and rest period and 3 months of therapy after high dose chemotherapy (HDC).
Filgrastim
Peripheral blood stem cells (PBSC) will be mobilized with filgrastim 10 mcg/kg/day IV
Busulfan
Conditioning for autologous Hematopoeitic Stem Cell Transplantation (HSCT) will consist of IV busulfan 2.0 mg/KBW once daily x 4 for days -5 to -2
Collaborators (1)
Incyte Corporation
INDUSTRY
Marina Kremyanskaya
OTHER